Among Medicaid-insured patients aged less than 65 years old, significantly shorter OS was observed. Another multivariable analysis found no statistical significance among Medicaid-insured and commercially insured patients.1
Key Takeaways
1. Differences in insurance coverage served as predictors for survival in patients with diffuse large B-cell lymphoma.
2. Patients in different racial or ethnic groups did not have any statistically significant differences in survival outcomes.
3. Those who were younger than 65 years old and insured through Medicaid had worse outcomes than those who were 65 and older.
Time to second-line therapy or death to any cause (TTNTD) was not significantly different across racial groups, continuing this trend. Once again, there were no statistically significant differences in Medicaid-insured compared with commercially insured patients in TTNTD based on the Cox model.1
These findings contradict conclusions from earlier studies in the literature, which typically reported worse outcomes in Black patients with DLBCL compared with white patients. However, more recent data has shown similar outcomes between the two groups; a retrospective analysis by Flowers et al. suggests that the racial disparity seen in these earlier studies could be due to a change in treatment regimen that occurred in 2011.1,3
In January of that year, the predominant treatment method for patients with DLBCL changed from cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) to rituximab and CHOP (R-CHOP). In Flowers et al. analysis, they found that there were no racial differences found in the use of R-CHOP, while Black patients faced worse survival among those treated with CHOP.3
Interestingly, the difference in survival between insurance plans was not observed in patients aged 65 years or older. The investigators suggested that “broadening access to affordable health insurance at an early point in the diagnostic process could reduce the survival disadvantage for patients without adequate coverage.”1
Using data from the Flatiron Health database allowed the researchers to analyze comprehensive and thorough patient information with long follow-ups. However, the use of a database such as this comes with limitations, such as the missingness of some variables. Further, the number of Medicare patients in the study was relatively small compared to the number of commercial patients.1
“Future studies are needed to further evaluate the relationship between race/ethnicity and insurance status and the impact on survival outcomes in patients with DLBCL, and should consider social, environmental, biologic, and patient-related factors that contribute to potential disparities in DLBCL survival,” the investigators concluded.1
REFERENCES
1. Jin Y, Li J, Mun Y, et al. Association of race/ethnicity and insurance with survival in patients with diffuse large B-cell lymphoma in a large real-world cohort. Cancer Medicine. 2024;13(16):e70032. doi:10.1002/cam4.70032
2. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Cancer Disparities. Accessed online September 3, 2024. https://seer.cancer.gov/statfacts/html/disparities.html
3. Flowers C, Shenoy P, Borate U, et al. Examining racial differences in diffuse large B-cell lymphoma presentation and survival. Leukemia & Lymphoma. 2012;54(2):268-276. doi:10.3109/10428194.2021.708751